Biogen (BIIB) Revenue & Revenue Breakdown
Biogen Revenue Highlights
Latest Revenue (Y)
$9.84B
Latest Revenue (Q)
$2.46B
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Biogen Revenue by Period
Biogen Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $9.84B | -3.32% |
| 2022-12-31 | $10.17B | -7.36% |
| 2021-12-31 | $10.98B | -18.32% |
| 2020-12-31 | $13.44B | -6.49% |
| 2019-12-31 | $14.38B | 6.88% |
| 2018-12-31 | $13.45B | 9.61% |
| 2017-12-31 | $12.27B | 7.21% |
| 2016-12-31 | $11.45B | 6.36% |
| 2015-12-31 | $10.76B | 10.93% |
| 2014-12-31 | $9.70B | 39.97% |
| 2013-12-31 | $6.93B | 25.66% |
| 2012-12-31 | $5.52B | 9.27% |
| 2011-12-31 | $5.05B | 7.04% |
| 2010-12-31 | $4.72B | 7.75% |
| 2009-12-31 | $4.38B | 6.83% |
| 2008-12-31 | $4.10B | 29.19% |
| 2007-12-31 | $3.17B | 69.41% |
| 2006-12-31 | $1.87B | 9.25% |
| 2005-12-31 | $1.71B | 7.38% |
| 2004-12-31 | $1.60B | 134.96% |
| 2003-12-31 | $679.18M | -40.86% |
| 2002-12-31 | $1.15B | 10.06% |
| 2001-12-31 | $1.04B | 12.62% |
| 2000-12-31 | $926.45M | 16.62% |
| 1999-12-31 | $794.43M | 42.48% |
| 1998-12-31 | $557.59M | 28.46% |
| 1997-12-31 | $434.04M | 56.64% |
| 1996-12-31 | $277.09M | 82.67% |
| 1995-12-31 | $151.69M | -2.98% |
| 1994-12-31 | $156.34M | 14.62% |
| 1993-12-31 | $136.40M | - |
Biogen generated $9.84B in revenue during NA 2023, up -3.32% compared to the previous quarter, and up 73.11% compared to the same period a year ago.
Biogen Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $2.46B | 12.03% |
| 2024-03-31 | $2.20B | -7.79% |
| 2023-12-31 | $2.39B | -5.69% |
| 2023-09-30 | $2.53B | 3.03% |
| 2023-06-30 | $2.46B | -0.28% |
| 2023-03-31 | $2.46B | -3.18% |
| 2022-12-31 | $2.54B | 1.42% |
| 2022-09-30 | $2.51B | -3.11% |
| 2022-06-30 | $2.59B | 2.26% |
| 2022-03-31 | $2.53B | -7.39% |
| 2021-12-31 | $2.73B | -1.62% |
| 2021-09-30 | $2.78B | 0.14% |
| 2021-06-30 | $2.77B | 3.01% |
| 2021-03-31 | $2.69B | -5.56% |
| 2020-12-31 | $2.85B | -15.51% |
| 2020-09-30 | $3.38B | -8.30% |
| 2020-06-30 | $3.68B | 4.17% |
| 2020-03-31 | $3.53B | -3.73% |
| 2019-12-31 | $3.67B | 1.98% |
| 2019-09-30 | $3.60B | -0.46% |
| 2019-06-30 | $3.62B | 3.64% |
| 2019-03-31 | $3.49B | -1.04% |
| 2018-12-31 | $3.53B | 2.54% |
| 2018-09-30 | $3.44B | 2.46% |
| 2018-06-30 | $3.36B | 7.20% |
| 2018-03-31 | $3.13B | -5.32% |
| 2017-12-31 | $3.31B | 7.45% |
| 2017-09-30 | $3.08B | -0.02% |
| 2017-06-30 | $3.08B | 9.52% |
| 2017-03-31 | $2.81B | -2.13% |
| 2016-12-31 | $2.87B | -2.84% |
| 2016-09-30 | $2.96B | 2.13% |
| 2016-06-30 | $2.89B | 6.14% |
| 2016-03-31 | $2.73B | -3.96% |
| 2015-12-31 | $2.84B | 2.21% |
| 2015-09-30 | $2.78B | 7.19% |
| 2015-06-30 | $2.59B | 1.44% |
| 2015-03-31 | $2.55B | -3.25% |
| 2014-12-31 | $2.64B | 5.15% |
| 2014-09-30 | $2.51B | 3.72% |
| 2014-06-30 | $2.42B | 13.70% |
| 2014-03-31 | $2.13B | 8.34% |
| 2013-12-31 | $1.97B | 7.55% |
| 2013-09-30 | $1.83B | 6.05% |
| 2013-06-30 | $1.72B | 21.79% |
| 2013-03-31 | $1.42B | -37.80% |
| 2012-12-31 | $2.27B | 107.23% |
| 2012-09-30 | $1.10B | -22.74% |
| 2012-06-30 | $1.42B | 9.98% |
| 2012-03-31 | $1.29B | -2.62% |
| 2011-12-31 | $1.33B | 1.28% |
| 2011-09-30 | $1.31B | 8.38% |
| 2011-06-30 | $1.21B | 0.44% |
| 2011-03-31 | $1.20B | -1.29% |
| 2010-12-31 | $1.22B | 3.68% |
| 2010-09-30 | $1.18B | -3.04% |
| 2010-06-30 | $1.21B | 9.36% |
| 2010-03-31 | $1.11B | -1.61% |
| 2009-12-31 | $1.13B | 0.58% |
| 2009-09-30 | $1.12B | 2.49% |
| 2009-06-30 | $1.09B | 5.48% |
| 2009-03-31 | $1.04B | -3.03% |
| 2008-12-31 | $1.07B | -2.20% |
| 2008-09-30 | $1.09B | 10.02% |
| 2008-06-30 | $993.44M | 5.44% |
| 2008-03-31 | $942.19M | 5.47% |
| 2007-12-31 | $893.30M | - |
Biogen generated $2.46B in revenue during Q2 2024, up 12.03% compared to the previous quarter, and up 100.08% compared to the same period a year ago.
Biogen Revenue Breakdown
Biogen Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| TYSABRI product | $2.03B | - | - | - | - |
| Interferon | $1.31B | - | - | - | - |
| Fumarate | $2.00B | - | - | - | - |
| MS Product Revenues | $5.43B | - | - | - | - |
| Royalty | $67.40M | $27.90M | $33.90M | $17.00M | $38.70M |
| Product and Service, Other | $485.10M | $18.20M | $48.60M | $383.20M | - |
| Product | $7.99B | - | - | - | - |
| Revenues from anti-cd20 therapeutic programs | $1.70B | - | - | - | - |
| SPINRAZA | $1.79B | - | - | - | - |
| Other corporate revenues | - | $427.70M | $719.10M | $584.50M | $459.40M |
Biogen's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (35.04%), MS Product Revenues (23.82%), TYSABRI product (8.91%), Fumarate (8.76%), SPINRAZA (7.87%), Revenues from anti-cd20 therapeutic programs (7.46%), Interferon (5.73%), Product and Service, Other (2.13%), and Royalty (0.30%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fumarate | $418.00M | $381.80M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| TYSABRI product | $462.20M | $431.30M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SPINRAZA | $429.10M | $341.30M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| MS Product Revenues | $1.15B | $1.08B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interferon | $250.90M | $243.60M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | - | $1.71B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Revenues from anti-cd20 therapeutic programs | - | $394.00M | $433.40M | $399.50M | $447.90M | $416.90M | $436.30M | $399.40M | $414.10M | $415.40M | $440.00M | $389.00M | $419.00M | $560.10M | $478.30M | $520.40M | $600.80M | $595.80M | $576.40M | $517.40M |
| Product and Service, Other | - | $184.60M | $197.50M | $319.10M | $191.60M | $129.50M | $97.90M | $66.10M | $126.20M | $157.80M | $99.00M | $93.30M | $132.00M | $125.70M | $407.60M | $109.30M | $145.70M | $109.60M | $160.00M | $292.40M |
| Royalty | - | - | $14.40M | $12.20M | $8.80M | $10.30M | $7.60M | $7.70M | $6.40M | $6.20M | $5.10M | $10.30M | $7.10M | $11.40M | $7.10M | $3.30M | $2.70M | $3.90M | - | - |
| Other corporate revenues | - | - | - | - | - | $114.20M | $81.20M | $113.60M | $143.80M | $87.10M | $83.20M | $119.60M | $110.00M | $395.50M | $94.00M | $122.10M | $93.10M | $105.20M | $264.10M | - |
Biogen's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: MS Product Revenues (42.43%), TYSABRI product (17.06%), SPINRAZA (15.83%), Fumarate (15.42%), and Interferon (9.26%).
Biogen Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| UNITED STATES | $3.47B | $1.14B | $1.10B | $5.50M | $1.02B |
| Asia | $672.10M | - | - | - | - |
| Europe | $2.40B | $100.00K | $200.00K | $200.00K | - |
| Segment Geographical Groups Of Countries Group Other | $64.00M | $61.80M | $80.30M | $78.30M | $76.60M |
| GERMANY | $926.20M | $1.16B | - | - | - |
| Europe, Excluding Germany | $100.00K | - | - | - | - |
| Non-US | - | $920.90M | $849.30M | $850.40M | $1.40M |
Biogen's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (46.05%), Europe (31.88%), GERMANY (12.30%), Asia (8.92%), Segment Geographical Groups Of Countries Group Other (0.85%), and Europe, Excluding Germany (0.00%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $846.70M | $746.10M | $130.30M | $93.50M | $138.30M | $127.90M | $129.90M | $284.50M | $288.00M | $281.10M | $299.80M | $273.30M | $270.80M | $304.20M | $244.10M | $277.70M | $269.50M | $263.00M | $264.30M | $245.00M |
| Non-US | $1.05B | $965.80M | $15.90M | $14.70M | $12.50M | $9.90M | $6.90M | $236.30M | $224.70M | $241.70M | $224.40M | $230.00M | $204.40M | $212.30M | $187.90M | $244.70M | $203.40M | $220.60M | $211.00M | $215.40M |
Biogen's latest quarterly revenue breakdown by geography, as of Jun 24: Non-US (55.43%), and UNITED STATES (44.57%).
Biogen Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| JNJ | Johnson & Johnson | $85.15B | $22.45B |
| MRK | Merck | $60.12B | $16.11B |
| PFE | Pfizer | $58.50B | $13.28B |
| ABBV | AbbVie | $54.32B | $14.46B |
| NVS | Novartis | $46.66B | $11.83B |
| BMY | Bristol-Myers Squibb Company | $45.01B | $12.20B |
| SNY | Sanofi | $43.07B | $11.12B |
| GSK | GSK | $30.33B | $7.36B |
| AMGN | Amgen | $28.19B | $8.39B |
| GILD | Gilead Sciences | $27.12B | $6.95B |
| BIIB | Biogen | $9.84B | $2.46B |
BIIB Revenue FAQ
What is Biogen’s yearly revenue?
Biogen's yearly revenue for 2023 was $9.84B, representing a decrease of -3.32% compared to 2022. The company's yearly revenue for 2022 was $10.17B, representing a decrease of -7.36% compared to 2021. BIIB's yearly revenue for 2021 was $10.98B, representing a decrease of -18.32% compared to 2020.
What is Biogen’s quarterly revenue?
Biogen's quarterly revenue for Q2 2024 was $2.46B, a 12.03% increase from the previous quarter (Q1 2024), and a 0.36% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $2.2B, a -7.79% decrease from the previous quarter (Q4 2023), and a -10.67% decrease year-over-year (Q1 2023). BIIB's quarterly revenue for Q4 2023 was $2.39B, a -5.69% decrease from the previous quarter (Q3 2023), and a -6.20% decrease year-over-year (Q4 2022).
What is Biogen’s revenue growth rate?
Biogen's revenue growth rate for the last 3 years (2021-2023) was -10.44%, and for the last 5 years (2019-2023) was -31.59%.
What are Biogen’s revenue streams?
Biogen's revenue streams in c 22 are TYSABRI product, Interferon, Fumarate, MS Product Revenues, Royalty, Product and Service, Other, Product, Revenues from anti-cd20 therapeutic programs, and SPINRAZA. TYSABRI product generated $2.03B in revenue, accounting 8.91% of the company's total revenue Interferon generated $1.31B in revenue, accounting 5.73% of the company's total revenue Fumarate generated $2B in revenue, accounting 8.76% of the company's total revenue MS Product Revenues generated $5.43B in revenue, accounting 23.82% of the company's total revenue Royalty generated $67.4M in revenue, accounting 0.30% of the company's total revenue, up 141.58% year-over-year. Product and Service, Other generated $485.1M in revenue, accounting 2.13% of the company's total revenue, up 2565.38% year-over-year. Product generated $7.99B in revenue, accounting 35.04% of the company's total revenue Revenues from anti-cd20 therapeutic programs generated $1.7B in revenue, accounting 7.46% of the company's total revenue SPINRAZA generated $1.79B in revenue, accounting 7.87% of the company's total revenue
What is Biogen’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Biogen was Product. This segment made a revenue of $7.99B, representing 35.04% of the company's total revenue.